MECP2 and Alzheimer disease: In the context of AD injury, DNA demethylation and MeCP2 phosphorylation at S421 reduce the binding of MeCP2 to these promoters, relieving transcriptional repression and permitting gene activation that controls the fate specification of NSCs/NPCs.